

*a6*  
units of *Taq* DNA polymerase. The reaction was run for 30 cycles with denaturation at 94°C for 1 min, annealing at 55°C for 1 minute, and extension at 72°C for 1 minute. The PCR products were electrophoresed through 1.5 % agarose gel containing ethidium bromide and images captured using NucleoTech imaging system (NucleoTech, San Mateo, CA).

IN THE CLAIMS:

Please substitute the following amended claim number 27 found on Page 107 for the original claim having the same number:

- a7*  
27. (Amended) The method of claim 25, wherein said therapeutic agent or uptake enhancer comprising a thiol compound comprises an amino acid sequence of:

N-acetyl-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Cys-(biotin)-Cys-NH<sub>2</sub> (SEQ ID NO:2)

N-acetyl-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-(biotin)-Cys-NH<sub>2</sub> (SEQ ID NO:3)

N-acetyl-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-D-Cys-(biotin)-Cys-NH<sub>2</sub>  
(SEQ ID NO:4)

N-acetyl-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-D-Lys-(biotin)-Cys-NH<sub>2</sub> (SEQ ID NO:5)

N-acetyl-Gln-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-D-Lys-(biotin)-Cys-NH<sub>2</sub> (SEQ ID NO:6); or

N-acetyl-Arg-Lys-Lys-Arg-Arg-Pro-Arg-Arg-Cys-(biotin)-Cys-NH<sub>2</sub> (SEQ ID NO:7).

N-acetyl-DCys-DLys-(biotin)-DArg-DArg-DArg-DGln-DArg-DArg-DLys-DLys-DArg-NH<sub>2</sub> (SEQ ID NO: 8)

or biologically and pharmaceutically acceptable salts thereof.

Please substitute the following amended claim number 46 found on Page 111 for the original claim having the same number:

46. (Amended) The method of claim 42, wherein said therapeutic agent or uptake enhancer comprising a thiol compound comprises an amino acid sequence of:

N-acetyl-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Cys-(biotin)-Cys-NH<sub>2</sub> (SEQ ID NO:2)

N-acetyl-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Lys-(biotin)-Cys-NH<sub>2</sub> (SEQ ID NO:3)

N-acetyl-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-D-Cys-(biotin)-Cys-NH<sub>2</sub> (SEQ ID NO:4)

N-acetyl-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-D-Lys-(biotin)-Cys-NH<sub>2</sub> (SEQ ID NO:5)

N-acetyl-Gln-Lys-Lys-Arg-Arg-Gln-Arg-Arg-D-Lys-(biotin)-Cys-NH<sub>2</sub> (SEQ ID NO:6); or

N-acetyl-Arg-Lys-Lys-Arg-Arg-Pro-Arg-Arg-Cys-(biotin)-Cys-NH<sub>2</sub> (SEQ ID NO:7).

N-acetyl-DCys-DLys-(biotin)-DArg-DArg-DArg-DGln-DArg-DArg-DLys-DLys-DArg-NH<sub>2</sub> (SEQ ID NO: 8)

or biologically and pharmaceutically acceptable salts thereof.

REMARKS

The specification has been amended to insert corrected sequence identifiers in compliance with the requirements of 37 CFR 1.821-1.825. A paper and electronic copy of the Sequence Listing has been mailed to a separate address. A paper copy is included herewith for the Examiner's reference and instructions are contained herein for the insertion of the Sequence Listing into the specification following the Abstract.

In view of the above and foregoing, completion of the filing of the present application and an early and favorable action on the merits are believed to be in order and are courteously solicited.